CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer
- 17 February 2022
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 106, 108598
- https://doi.org/10.1016/j.intimp.2022.108598
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer ModelsCancer Research, 2014
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 EfficacyScience Translational Medicine, 2014
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 AxisClinical Cancer Research, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- CCL2 Blockade Augments Cancer ImmunotherapyCancer Research, 2010
- Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to InvasionCancer Research, 2007
- Immunotherapy for pancreatic cancer — science driving clinical progressNature Reviews Cancer, 2005
- CCL2 (monocyte chemoattractant protein-1) and cancerSeminars in Cancer Biology, 2004
- Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.Proceedings of the National Academy of Sciences of the United States of America, 1994